PD98059
(Synonyms: 2-(2-氨基-3-甲氧基苯基)-4H-1-苯并吡喃-4-酮) 目录号 : GC12819
D98059是一种有效的选择性MEK抑制剂，IC50为2 μM。
Cas No.:167869-21-8
Sample solution is provided at 25 µL, 10mM.
PD98059 is a potent and selective MEK inhibitor with an IC50 of 2 μM. PD98059 binds to the inactive form of MEK, thereby preventing the upstream kinase from activating MEK1/2. Besides, PD98059 is a ligand for the AHR and functions as an AHR antagonist[1-3].
PD98059(10 µM PD98059;14days) combined with TGF-β1 transforms human UDSCs (hUDSCs) into smooth muscle cells (SMCs)[4]. PD98059 (10 μM PD98059 ;24 h) suppresses the ERK pathway and the epithelial mesenchymal transition process(EMT) process in low dose cisplatin-resistant ovarian cancer cells(SKOV-3/DDP) [5]. PD98059 arrested Hec50co cells at the G0/G1 phase, the combination with PTX treatment increased accumulation at both the G0/G1 and G2/M phase[6]. PD98059(1, 5, 10, 20 and 50 µM；24h) inhibited MCF-7 and MDA-MB-231 cells proliferation in a dose-dependent manner[7].
PD98059(5 mg/kg/day; i.p; 2 weeks) treatment reduced adverse effects, including micronucleus (MN) formation, lipid peroxidation, and glutathione(GSH) oxidation in the EAE model[8].PD98059(0.15/0.3mg/kg PD98059; i.v. gtt) protects the brain against mitochondrial-mediated apoptosis and autophagy at 24 h post-resuscitation in rats subjected to cardiac arrest/cardiopulmonary resuscitation (CA/CPR), which is linked with the downregulation of dynamin-related protein 1 (Drp1) expression[9]. Treatment of mice with PD98059(10mg/kg; i.p; bolus) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan[10].
References:
[1]. Reiners JJ Jr, Lee JY, Clift RE, et.al. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol. 1998 Mar;53(3):438-45. doi: 10.1124/mol.53.3.438. PMID: 9495809.
[2]. Dudley DT, Pang L, et.al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9. doi: 10.1073/pnas.92.17.7686. PMID: 7644477; PMCID: PMC41210.
[3]. Attia SM, Ahmad SF, et.al.The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis. Mutat Res Genet Toxicol Environ Mutagen. 2021 Jan-Feb;861-862:503278. doi: 10.1016/j.mrgentox.2020.503278. Epub 2020 Oct 29. PMID: 33551096.
[4]. Hwang Y, Cha SH, et.al.Combination of PD98059 and TGF-β1 Efficiently Differentiates Human Urine-Derived Stem Cells into Smooth Muscle Cells. Int J Mol Sci. 2021 Sep 29;22(19):10532. doi: 10.3390/ijms221910532. PMID: 34638875; PMCID: PMC8508912.
[5]. Hou L, Hou X, et.al.PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process. Cancer Biomark. 2017 Dec 12;21(1):187-194. doi: 10.3233/CBM-170644. PMID: 29103028.
[6].Wiwatchaitawee K, Mekkawy AI, et.al. The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles. Drug Deliv Transl Res. 2022 Jul;12(7):1684-1696. doi: 10.1007/s13346-021-01065-7. Epub 2021 Oct 11. PMID: 34635984; PMCID: PMC8995400.
[7]. Zhao Y, Ge CC, et.al. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation. Oncol Rep. 2017 Nov;38(5):3055-3063. doi: 10.3892/or.2017.5955. Epub 2017 Sep 13. PMID: 29048617.
[8]. Attia SM, Ahmad SF, et.al.The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis. Mutat Res Genet Toxicol Environ Mutagen. 2021 Jan-Feb;861-862:503278. doi: 10.1016/j.mrgentox.2020.503278. Epub 2020 Oct 29. PMID: 33551096.
[9]. Zheng JH, Xie L, et.al. PD98059 protects the brain against mitochondrial-mediated apoptosis and autophagy in a cardiac arrest rat model. Life Sci. 2019 Sep 1;232:116618. doi: 10.1016/j.lfs.2019.116618. Epub 2019 Jun 29. PMID: 31265854.
[10].Di Paola R, Galuppo M, et.al.PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice. Pharmacol Res. 2010 Feb;61(2):175-87. doi: 10.1016/j.phrs.2009.09.008. Epub 2009 Oct 9. PMID: 19819333.
D98059是一种有效的选择性MEK抑制剂,IC50为2 μM。PD98059结合无活性形式的MEK,从而阻止上游激酶激活MEK1/2。此外,PD98059是AHR的配体,具有AHR拮抗剂的功能[1-3]。
PD98059(10 µM PD98059;14days)结合TGF-β1可将人尿源干细胞HUDSCs转化为平滑肌细胞(SMCs) [4]。PD98059 (10 μM PD98059 ;24 h)抑制低剂量顺铂耐药卵巢癌细胞(SKOV-3/DDP)的ERK通路和上皮间充质转化EMT过程[5]。PD98059在G0/G1期阻滞了Hec50co细胞,与PTX联合处理增加了G0/G1和G2/M期的积累[6]。PD98059(1、5、10、20 and 50µM;24h)呈剂量依赖性抑制MCF-7和MDA-MB-231细胞的增殖[7]。
在EAE模型中,PD98059(5 mg/kg/day; i.p; 2 weeks)治疗减少了不良反应,包括微核(MN)形成、脂质过氧化和谷胱甘肽(GSH)氧化[8]。在心脏骤停/心肺复苏(CA/CPR)大鼠复苏后24小时,PD98059(0.15/0.3mg/kg PD98059; i.v. gtt)保护大脑免受线粒体介导的细胞凋亡和自噬,这与动力蛋白相关蛋白1 (Drp1)表达下调有关[9]。用PD98059(10mg/kg; i.p; bolus)治疗小鼠可减少由zymosan酶引起的腹膜渗出和多形核细胞的迁移[10]。
|
Kinase activity Assay[1]： |
|
|
Preparation method |
Incorporation of 32P into myelin basic protein (MBP) was assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1) with(or not) PD98059. Assays were conducted in 50 μl of 50 mM Tris, pH 7.4，10 mM MgCl2，2 mM EGTA，10 μM [y-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30℃ for 15 min, reactions were stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP was resolved by SDS/PAGE(10%). |
|
Applications |
D98059 is a non-ATP-competitive MEK inhibitor with an IC50 of 2 μM. |
|
Cell experiment [2]: |
|
|
Cell lines |
MCF-7 and MDA-MB-231 cells |
|
Preparation method |
Cells were seeded in 96-well plates. After cells grew to 30% of the bottom of cell culture plates, various concentrations of PD980589 (1, 5, 10, 20 and 50 µM) were added to the cells and incubation was carried out for 24 h. |
|
Reaction Conditions |
1, 5, 10, 20 and 50 µM；24h |
|
Applications |
PD98059 inhibited MCF-7 and MDA-MB-231 cells proliferation in a dose-dependent manner. |
|
Animal experiment [3]: |
|
|
Animal models |
SJL/J mice (experimental autoimmune encephalomyelitis (EAE) model) |
|
Preparation method |
Mice received a single daily intraperitoneal injection of PD98059, or sham with equal amounts of 1% DMSO, once they reached a neurological disability score of >2 (i.e., day 14). Mice were euthanized 24 h after the last injection with PD98059, and bone marrow cells and spinal cord tissues were harvested. |
|
Dosage form |
5 mg/kg/day; i.p; 2 weeks |
|
Applications |
PD98059 treatment reduced adverse effects, including micronucleus (MN) formation, lipid peroxidation, and glutathione (GSH) oxidation in the EAE model. |
|
References: [1]. Dudley DT, Pang L, et.al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9. doi: 10.1073/pnas.92.17.7686. PMID: 7644477; PMCID: PMC41210. [2]. Zhao Y, Ge CC, et.al.MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation. Oncol Rep. 2017 Nov;38(5):3055-3063. doi: 10.3892/or.2017.5955. Epub 2017 Sep 13. PMID: 29048617. [3]. Attia SM, Ahmad SF, et.al. The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis. Mutat Res Genet Toxicol Environ Mutagen. 2021 Jan-Feb;861-862:503278. doi: 10.1016/j.mrgentox.2020.503278. Epub 2020 Oct 29. PMID: 33551096. |
|
| Cas No. | 167869-21-8 | SDF | |
| 别名 | 2-(2-氨基-3-甲氧基苯基)-4H-1-苯并吡喃-4-酮 | ||
| 化学名 | 2-(2-amino-3-methoxyphenyl)chromen-4-one | ||
| Canonical SMILES | COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2 | ||
| 分子式 | C16H13NO3 | 分子量 | 267.28 |
| 溶解度 | ≥ 40.23 mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7414 mL | 18.707 mL | 37.4139 mL |
| 5 mM | 0.7483 mL | 3.7414 mL | 7.4828 mL |
| 10 mM | 0.3741 mL | 1.8707 mL | 3.7414 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Inhibition of p-STAT3 (Ser727) augments the effects of CPX on the autophagy of GC cells.b Western blotting analysis of p-STAT3 (Ser727), p-STAT3 (Tyr705), STAT3, p-ERK (Thr202/Tyr204), and ERK1/2 in GC cells treated with a serial concentration of PD98059 for 24 h.
Western blotting analysis of p-STAT3 (Ser727), p-STAT3 (Tyr705), STAT3, p-ERK (Thr202/Tyr204), and ERK1/2 in GC cells treated with a serial concentration of PD98059 （Glpbio）for 24 h.
Cell Death & Disease 13.11 (2022): 1007. PMID: PMID: 36443287 IF: 9.0002 -
Related Biological Data
tBHQ induces the Nrf2-dependent antioxidant responses in glutamate-induced R28 cells A. Expression of Nrf2 in R28 cells under fluorescence microscopy.B. Effects of pretreatment with inhibitors of intermediate proteins on cell viability.
We pretreated cells for 30 min with inhibitors of ERK (PD98059)（Glpbio）, JNK (SP600125), p38 (SB203580) or Akt (MK-2206) to determine if tBHQ affects these intermediate proteins .
Biomedicine & Pharmacotherapy 152 (2022): 113117. PMID: 35653886 IF: 6.5298 -
Related Biological Data
Effects of 5-HT and 5-HT7R selective agonist LP-12 combined with SB269970 on melanin contents, dendrite, or migration in B16F10 cells. B16F10 cells were pre-incubated with SP600125 (10 μM) and PD98059 (10 μM) for 2 h prior to the addition of LP-12 (200 nM), and then incubated for 72 h for the measurement of melanin content.
B16F10 cells were pre-incubated with PD98059（Glpbio） (10 μM) for 2 h prior to the addition of LP-12(200 nM), and then incubated for 72 h for the measurement of melanin content.
The FASEB Journal 37.4 (2023): e22893. PMID: 36961387 IF: 5.8339